CIA remains focused on driving growth through product development, expanding distribution, including international market penetration, and enhancing agent/client service platforms. Elevated endowment maturities are near-term challenges. We introduce our 2027 estimates that include 5% premium revenue growth as strong first year premiums drive renewal premium revenue. Despite operating expenses to support growth, we forecast a 22% EPS improvement. Our lower 2026 estimates reflect elevated endowment maturities outpacing our original expectations. We continue to expect endowment maturities will peak in 2025, and for pressure on renewal premium revenue to be somewhat offset by recent strength in first year premium growth. CIA recorded a record level of direct insurance in force of $5.38 billion at 3Q:25 ($5.35 billion at 2Q:25), due to expanded distribution and sales of new products. An outsized gain in net investment income and lower claims and surrender payments drove EPS of $0.07 in 3Q:25, outpacing $0.04 in 3Q:24. The balance sheet remains debt free and capital positioning is healthy, aided by CIA's reinsurance operations. Financial strength is supported by strong cash flow generation, with a nearly 20-year history of positive operating cash flow. We maintain our $5 price target on CIA shares, applying a 0.8x multiple to our new 2027 book value per share estimate of $7.12. Previously we applied a 0.8x multiple applied to our 2026 book value per share estimate of $6.81. Book value per share equaled $6.26 at 3Q:25. Our Moderate risk rating reflects CIA's rapid pace of growth and increasing capital requirements and liquidity needs.